HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS		QUICK SEARCH:   [advanced] Author: Keyword(s): Year:  Vol:  Page:

This Article Full Text Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Citation Map Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Add to Personal Folders Download to citation manager Author home page(s): Wulf Dietrich Hans Meisner Permission Requests Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Dietrich, W. Articles by Meisner, H. Search for Related Content PubMed PubMed Citation Articles by Dietrich, W. Articles by Meisner, H.

Ann Thorac Surg 1998;65:70-77
© 1998 The Society of Thoracic Surgeons

---

Original Articles: Cardiovascular

Influence of High- and Low-Dose Aprotinin on Activation of Hemostasis in Open Heart Operations

Department of Anesthesiology, German Heart Center Munich, Munich, Germany
Department of Cardiovascular Surgery, German Heart Center Munich, Munich, Germany

Accepted for publication July 12, 1997.

Dr Dietrich, Department of Anesthesiology, German Heart Center Munich, Lazarettstrasse 36, D-80636 Munich, Germany (e-mail: dietrich@dhm.mhn.de).

Background. The protease inhibitor aprotinin reduces hemostatic activation and blood loss after cardiac operations. The aim of the present study was to investigate the influence of two different aprotinin doses on hemostatic activation and to identify the most effective dose to reduce the postoperative bleeding tendency.

Methods. In a prospective, randomized, double-blind clinical trial, 230 patients scheduled for routine open heart operations received either high-dose (group H) or low-dose (group L) aprotinin. Primary outcome measures were the level of F₁₊₂ prothrombin fragments as a marker of thrombin generation, the level of D-dimers as an indicator of fibrinolysis, and the amount of postoperative blood loss. Allogeneic blood transfusion was recorded as a secondary outcome measure.

Results. Aprotinin plasma concentrations 5 minutes after the onset of cardiopulmonary bypass were 166 ± 45 kallikrein inactivator units per milliliter in group H and 118 ± 30 kallikrein inactivator units per milliliter in group L (p < 0.05). Fibrinolytic activation was reduced significantly in group H compared with group L: the level of D-dimers at the end of CPB was 1,027 ± 781 ng/mL and 1,977 ± 1,001 ng/mL, respectively, in the two groups (p < 0.05). However, thrombin generation (F₁₊₂ fragments) did not differ between the two groups (7.4 ± 3.5 nmol/L in group H and 8.6 ± 4.3 nmol/L in group L). Twenty-four–hour postoperative blood loss was 663 ± 461 mL in group H compared with 877 ± 513 mL in group L (p < 0.05), and the corresponding allogeneic blood requirement was 1.3 ± 1.9 U in group H and 1.9 ± 2.3 U in group L (p < 0.05).

Conclusions. A high-dose aprotinin regimen was significantly more effective than a low-dose regimen in attenuating fibrinolysis and reducing the bleeding tendency and allogeneic blood requirements, but not in reducing F₁₊₂ prothrombin fragments. High-dose aprotinin therapy appears to be superior to low-dose therapy.

This article has been cited by other articles:

				W. Dietrich, R. Busley, and M. Kriner High-Dose Aprotinin in Cardiac Surgery: Is High-Dose High Enough?: An Analysis of 8281 Cardiac Surgical Patients Treated with Aprotinin Anesth. Analg., November 1, 2006; 103(5): 1074 - 1081. [Abstract] [Full Text] [PDF]

				A. Koster, S. Huebler, F. Merkle, T. Hentschel, M. Grundel, T. Krabatsch, L. Tambeur, M. Praus, H. Habazettl, W. M. Kuebler, et al. Heparin-Level-Based Anticoagulation Management During Cardiopulmonary Bypass: A Pilot Investigation on the Effects of a Half-Dose Aprotinin Protocol on Postoperative Blood Loss and Hemostatic Activation and Inflammatory Response Anesth. Analg., February 1, 2004; 98(2): 285 - 290. [Abstract] [Full Text] [PDF]

				L. Englberger, B. Kipfer, P. A. Berdat, U. E. Nydegger, and T. P. Carrel Aprotinin in coronary operation with cardiopulmonary bypass: does "low-dose" aprotinin inhibit the inflammatory response? Ann. Thorac. Surg., June 1, 2002; 73(6): 1897 - 1904. [Abstract] [Full Text] [PDF]

				G. A. Nuttall, D. N. Fass, L. J. Oyen, W. C. Oliver Jr., and M. H. Ereth A Study of a Weight-Adjusted Aprotinin Dosing Schedule During Cardiac Surgery Anesth. Analg., February 1, 2002; 94(2): 283 - 289. [Abstract] [Full Text] [PDF]

				P. Van der Linden, S. De Hert, A. Daper, A. Trenchant, D. Jacobs, C. De Boelpaepe, P. Kimbimbi, P. Defrance, and G. Simoens A standardized multidisciplinary approach reduces the use of allogeneic blood products in patients undergoing cardiac surgery : [L'approche systematique et multidisciplinaire diminue le recours aux produits sanguins allogenes chez les malades operes du coeur] Can J Anesth, October 1, 2001; 48(9): 894 - 901. [Abstract] [Full Text] [PDF]

				S. M. Beath, G. A. Nuttall, D. N. Fass, W. C. Oliver Jr., M. H. Ereth, and L. J. Oyen Plasma Aprotinin Concentrations During Cardiac Surgery: Full- Versus Half-Dose Regimens Anesth. Analg., August 1, 2000; 91(2): 257 - 264. [Abstract] [Full Text] [PDF]

				F. Forestier, S. Belisle, D. Robitaille, R. Martineau, L. P. Perrault, and J.-F. Hardy Low-dose aprotinin is ineffective to treat excessive bleeding after cardiopulmonary bypass Ann. Thorac. Surg., February 1, 2000; 69(2): 452 - 456. [Abstract] [Full Text] [PDF]

				C. J. O’Connor, D. V. Brown, M. Avramov, S. Barnes, H. N. O’Connor, and K. J. Tuman The Impact of Renal Dysfunction on Aprotinin Pharmacokinetics During Cardiopulmonary Bypass Anesth. Analg., November 1, 1999; 89(5): 1101 - 1101. [Abstract] [Full Text] [PDF]